Comparative nonclinical assessments of the biosimilar PF-06410293 and originator adalimumab
Open Access
- 1 April 2020
- journal article
- research article
- Published by Elsevier BV in Regulatory Toxicology and Pharmacology
- Vol. 112, 104587
- https://doi.org/10.1016/j.yrtph.2020.104587
Abstract
No abstract availableKeywords
Funding Information
- US
- Food and Drug Administration
- Pfizer
- Pfizer
This publication has 13 references indexed in Scilit:
- Pharmacokinetic and toxicology comparator testing of biosimilar drugs – Assessing needRegulatory Toxicology and Pharmacology, 2017
- Waiving in vivo studies for monoclonal antibody biosimilar development: National and global challenges.mAbs, 2016
- Biosimilars entering the clinic without animal studiesmAbs, 2014
- Nonclinical Development of A Biosimilar: The Current LandscapeBioanalysis, 2013
- Cellular Mechanisms of TNF Function in Models of Inflammation and AutoimmunityPublished by S. Karger AG ,2010
- Recognition by TNF-α of the GPI-anchor glycan induces apoptosis of U937 cellsArchives of Biochemistry and Biophysics, 2004
- Immunohistochemical Recognition of Human Follicular Dendritic Cells (FDCs) in Routinely Processed Paraffin SectionsJournal of Histochemistry & Cytochemistry, 2002
- Purification and catalytic properties of human caspase family membersCell Death & Differentiation, 1999
- Caspases: Enemies WithinScience, 1998
- Caspases: key mediators of apoptosisCell Chemical Biology, 1998